IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche
In This Article:
TG Therapeutics rallied Wednesday after Roche's rival multiple sclerosis treatment, Ocrevus, missed its mark in a study.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
TG Therapeutics rallied Wednesday after Roche's rival multiple sclerosis treatment, Ocrevus, missed its mark in a study.